Digital Biomarkers Market Size & Share 2026-2035

Digital Biomarkers Market Size

The global digital biomarkers market was valued at USD 4.8 billion in 2025 and is projected to expand from USD 6.0 billion in 2026 to USD 60.6 billion by 2035, reflecting a CAGR of 29.2% over 2026–2035. Digital biomarkers convert physiological, behavioral, functional, or environmental signals captured through connected devices into measurements that can inform disease detection, monitoring, prognosis, or therapeutic response.

The market is advancing because continuous measurement addresses a limitation of episodic care: clinically meaningful changes in cardiac rhythm, mobility, sleep, respiratory status, speech, and treatment adherence may occur outside a scheduled encounter. This is especially relevant in chronic conditions, which account for 41 million deaths each year globally, according to the World Health Organization ^{[1]World Health Organization - Boosting digital health can help prevent millions of deaths from noncommunicable diseases, September 2024 - who.int}. The value of a digital biomarker therefore rests on more than device connectivity; it depends on whether the signal is analytically valid, interpretable in context, and usable within clinical or trial workflows.

Regulatory and reimbursement developments are reducing the distance between digital measurement and commercial deployment. The U.S. Food and Drug Administration's framework for digital health technologies in drug and biological product development addresses the use of device-derived data and digital endpoints in clinical development ^{[2]U.S. Food and Drug Administration - Framework for the Use of Digital Health Technologies in Drug and Biological Product Development, March 2023 - fda.gov}. In Europe, the European Medicines Agency's qualification process provides a route for digital technology-based methodologies to support medicinal-product development ^{[7]European Medicines Agency - Questions and answers: Qualification of digital technology-based methodologies to support approval of medicinal products - ema.europa.eu}. These mechanisms matter because they allow sponsors to build evidence packages around repeatable digital measures rather than treating connected-device data solely as exploratory evidence.

Remote monitoring has become a material deployment channel. Medicare payments for remote patient monitoring reached USD 536 million in 2024, up from USD 408 million in 2023, with nearly one million enrollees served through more than 10,000 billing practices. Payment expansion does not automatically validate every device-generated signal, but it creates an operating environment in which providers can invest in data capture, patient onboarding, and alert-management processes.

This transition favors platforms that can manage the full chain from patient engagement and signal capture to data quality control, algorithm validation, and regulatory documentation. It also creates a separation between consumer engagement features and clinical-grade digital biomarkers. A widely available device may lower acquisition costs, but its commercial value remains limited unless the resulting measurement is fit for a specific use context and can be interpreted without overwhelming clinicians with unprioritized alerts.

Key Drivers

Chronic disease management requires longitudinal evidence

Cardiovascular disease, diabetes, respiratory conditions, neurological disorders, and psychiatric conditions often produce variable symptoms and functional changes that are poorly represented by occasional office-based assessments. Digital biomarkers can capture repeatable measures of movement, sleep, heart rhythm, respiratory behavior, medication use, glucose patterns, cognition, and speech in a patient's daily environment. That capability supports earlier recognition of deterioration and gives drug developers access to outcomes that may be more frequent and sensitive than conventional visit-based assessments.

The addressable need is reinforced by the global burden of noncommunicable diseases. The World Health Organization reports that such conditions cause 74% of deaths worldwide. Digital biomarkers do not eliminate the need for clinical assessment; rather, they can increase the temporal resolution of evidence available to clinicians, sponsors, and payers. This is particularly valuable where treatment decisions depend on detecting change over days or weeks rather than at a single clinic visit.

Algorithmic interpretation is improving the utility of device data

Connected devices produce high-frequency data, but raw data alone rarely support a clinical action. The market has expanded as machine-learning models improve the conversion of sensor signals into interpretable measures. In cardiac care, AliveCor received FDA clearance in June 2024 for its KAI 12L AI technology and Kardia 12L ECG System, which use a reduced-leadset acquisition to support detection of multiple cardiac determinations ^{[3]AliveCor - AliveCor Announces Dual FDA Clearance of KAI 12L AI Technology and Kardia 12L ECG System, June 2024 - alivecor.com}. The development illustrates how a portable device can move beyond basic signal capture when paired with a defined analytical claim and regulatory evidence.

Neurological and cognitive applications are following a related route. Research on passive wearable and mobile data has shown that physiological, sleep, and behavioral features can be associated with cognitive and mental-health outcomes, while emphasizing the need for validation and clinically appropriate implementation. The commercial consequence is that algorithm development is becoming a central competitive layer: differentiation increasingly lies in the validity, reproducibility, and intended use of the derived measure rather than in the physical sensor alone.

Wearables and mobile applications lower the friction of repeated measurement

Wearables lead the market because they combine relatively familiar user experiences with continuous data capture. The 42.5% wearable share in 2025 reflects applications such as cardiac rhythm assessment, seizure monitoring, mobility measurement, sleep analysis, and medication-use tracking. Empatica's EpiMonitor received FDA 510(k) clearance for seizure monitoring, demonstrating the regulatory relevance of a wearable-based measurement in a high-acuity indication ^{[4]U.S. Food and Drug Administration - 510(k) Premarket Notification K232915: EpiMonitor - accessdata.fda.gov}.

Mobile-based applications extend the market by using smartphones as both a patient interface and a sensor platform. Their 28.2% share reflects lower hardware barriers for assessments involving speech, motor activity, cognition, adherence, and patient-reported information. Roche and Inovigate's patent for smartphone-derived measures of multiple-sclerosis progression illustrates the broader platform model: commodity device hardware can support differentiated clinical evidence when paired with validated performance tasks and reference methods.

Remote monitoring reimbursement supports provider adoption

Remote monitoring reimbursement is important because it converts continuous data collection from a stand-alone technology expense into an operational service. Medicare's 2024 payment growth indicates that remote monitoring has moved beyond a limited pilot market in the United States. Digital biomarkers can benefit from this infrastructure when their outputs help prioritize patients, identify deterioration, or document treatment adherence.

Provider adoption will nonetheless depend on workflow design. A system that generates clinically relevant data but requires excessive manual review can add cost rather than improve care. The most scalable deployments are likely to be those that combine reliable patient onboarding, signal-quality controls, escalation thresholds, and integration with care-team responsibilities.

Key Restraints

Evidence-generation and implementation costs remain substantial

Clinical-grade digital biomarkers require more than a connected device. Development costs include analytical validation, clinical validation, cybersecurity controls, quality systems, regulatory documentation, data governance, and post-deployment monitoring. For decentralized trials, sponsors also incur device provisioning, multilingual support, participant training, logistics, data reconciliation, and endpoint-management costs.

These requirements create a meaningful divide between an appealing digital feature and a deployable clinical measurement. The burden is highest in indications where the most valuable signals are multimodal or where patient populations have low tolerance for repeated device use. Smaller sponsors and providers may therefore favor outsourced platforms that can supply validated devices, operational support, and data-management capabilities rather than build these capabilities internally.

Clinical workflow capacity limits scalable use

Digital biomarkers shift work rather than simply reducing it. Clinicians must understand the difference between a device alert, a validated biomarker, and a diagnosis; care teams need procedures for responding to signals; and organizations must manage false positives, missing data, and uneven patient adherence. Model performance in research settings does not guarantee that the same result will be achieved across diverse patients, device behaviors, and real-world workflows.

The skills constraint is particularly relevant in clinical development. Digital endpoint programs require expertise across clinical outcome assessment, signal processing, biostatistics, privacy, device operations, and regulatory science. This creates demand for specialist firms, but it also increases dependency on their ability to standardize data quality across sites, geographies, and device types.

Reimbursement and regulatory progress remain uneven across use cases

Regulatory acceptance, reimbursement coverage, and clinical adoption do not advance at the same pace. The FDA's digital-health framework and EMA qualification processes support evidence development, but they do not guarantee payment for each product or endpoint,. Cardiac, respiratory, and diabetes-related monitoring have clearer operational and payment precedents than many psychiatric, neurological, and musculoskeletal applications.

The constraint is therefore not limited to technology. Companies must demonstrate that their biomarker has a defined use context, produces a meaningful clinical or operational advantage, and can be embedded in an economically sustainable workflow. Markets with weaker reimbursement systems may adopt lower-cost mobile approaches first, while more intensive sensor and service models remain concentrated in clinical trials or higher-resource settings.

Accordingly, scale will not accrue evenly across all digital biomarkers. Monitoring applications with established signals, recurring use, and recognizable payment pathways have a stronger commercial foundation than exploratory measures. The opportunity for suppliers is increasingly tied to reducing the operational cost of validation, deployment, and interpretation rather than merely adding new data modalities.

Digital Biomarkers Market Segment Analysis

By type

Wearables represented 42.5% of market revenue in 2025. Their lead reflects the combination of continuous capture, patient familiarity, and expanding clinical use cases across cardiac rhythm, movement, sleep, seizure, and metabolic monitoring. Wearables are particularly suited to repeated physiological measurement, but their competitive advantage depends on data quality, adherence, and the clinical validity of the associated algorithm.

Mobile-based applications accounted for 28.2% of 2025 revenue. They provide a distribution route for active assessments, passive sensing, electronic clinical outcome assessments, and voice-based tools without requiring dedicated hardware. This makes them particularly relevant where the digital biomarker is derived from speech, touchscreen interaction, gait tasks, or patient-reported activity. Their lower initial hardware cost can broaden access, although variation in smartphone models, operating systems, and user behavior can complicate standardization.

Sensors held 18.4% of the market. This category includes specialized biosensors and ambient systems designed to collect information without placing a device on the patient. Contact-free approaches may be useful for people with low wearable adherence or cognitive impairment, but their deployment requires careful attention to home environment, privacy, and signal specificity.

Other types, including voice biomarkers and software analytics platforms, represented approximately 10.9%. This segment is strategically important because it demonstrates that an actionable digital biomarker may arise from existing infrastructure rather than from a new hardware purchase. Speech and software-derived measures can support scalable collection, but their clinical role depends on evidence that linguistic or behavioral variation reflects the intended health construct rather than language, culture, device quality, or situational factors.

By clinical practice

Monitoring accounted for 45.8% of 2025 revenue and is expected to reach USD 27.8 billion by 2035. Its leadership reflects the direct relevance of continuous data to chronic disease surveillance, treatment adherence, adverse-event detection, and decentralized trial operations. Monitoring also aligns most closely with established remote-care models because the value of repeated observation is relatively intuitive to providers and payers.

Diagnostic applications represented 32.6% in 2025. These measures seek to identify disease presence, severity, or stage through a digital output that augments traditional assessment. FDA-cleared cardiac technologies and AI-enabled imaging tools demonstrate the potential of diagnostic digital biomarkers, but diagnostic use carries a high evidentiary bar because errors can affect downstream treatment decisions.

Predictive and prognostic applications held 15.2% of market revenue. They focus on estimating future risk or likely disease trajectory, including neurological and functional decline. Their value can be substantial in trial enrichment, early intervention, and personalized follow-up, but the commercial pathway depends on showing that a prediction changes a decision and improves an outcome.

Other clinical practices accounted for approximately 6.4%. These include pharmacodynamic, safety, and treatment-response measures. Adoption is likely to be strongest where a digital measure can capture a treatment effect that conventional assessments miss or measure only infrequently.

By therapeutic area

CVMD led the market with a 22.5% share in 2025. Cardiac rhythm monitoring, physiological surveillance, and related remote-care workflows offer a mature route to deployment because the underlying signals are measurable and clinical escalation pathways are relatively well defined. The June 2024 FDA clearance of AliveCor's KAI 12L and Kardia 12L system underscores the continued movement of cardiac analysis toward portable, algorithm-supported formats.

Diabetes accounted for 20.2% of 2025 revenue. Continuous glucose data remains one of the clearest examples of a digital measurement directly influencing routine disease management. NHS England's five-year hybrid closed-loop implementation strategy, published in 2024, supports broader use of connected glucose-management infrastructure for eligible people with type 1 diabetes ^{[5]NHS England - Hybrid Closed Loop Technologies: 5-Year Implementation Strategy, January 2024 - england.nhs.uk}.

Respiratory disorders represented 13.6%, supported by inhaler-use monitoring, symptom tracking, and respiratory-signal analysis. Adherium's Hailie platform demonstrates how connected inhaler data can support medication-use monitoring in asthma and chronic obstructive pulmonary disease settings ^{[6]Adherium Limited - U.S. FDA 510(k) Clearance for GSK pMDI Inhaler Users to Remotely Monitor Physiological Parameters, November 2022 - adherium.com}. The segment's expansion depends on whether these measures can reduce exacerbations, improve adherence, or support reimbursable therapeutic-monitoring workflows.

Psychiatric disorders accounted for 12.4%, while neurological disorders represented 10.2%. These fields have a strong need for repeated functional and behavioral measurement, but also face difficult questions around privacy, interpretability, and clinical actionability. Voice, sleep, movement, and smartphone-derived cognitive measures can offer useful longitudinal evidence, yet their utility must be demonstrated separately across conditions and patient populations.

Sleep and movement diseases held 8.7% of the market, and musculoskeletal disorders accounted for 7.4%. Both depend heavily on mobility, activity, gait, balance, and sleep-derived measures that can reveal functional changes outside a clinic. Other therapeutic areas represented approximately 5.0%, including applications in pain management and oncology where digital measures may help capture function, symptoms, or treatment tolerability.

By end use

Healthcare providers held the largest end-use share at 38.4% in 2025. Their purchasing decisions are shaped by reimbursement, clinical workflow capacity, patient engagement, and the ability to integrate measurement outputs into care management. The provider segment will benefit most where biomarker data can be translated into defined triage or treatment actions.

Pharmaceutical and biotechnology companies represented 26.7%. These organizations use digital biomarkers to improve endpoint sensitivity, support decentralized studies, characterize treatment response, and collect real-world evidence. The commercial requirement is stringent: sponsors need measures that are analytically robust, clinically meaningful, and sufficiently documented for regulatory interaction.

Academic and research institutions held approximately 19.4%, reflecting their role in discovery, validation, and longitudinal evidence generation. Payers accounted for 15.5%, with interest concentrated in remote monitoring, population-risk management, and the potential to prevent expensive acute-care events through earlier intervention.

CVMD and diabetes have an early advantage because their signals are comparatively established and can connect to existing clinical pathways. Neurological, psychiatric, sleep, and musculoskeletal applications offer substantial upside, but their growth will depend on whether suppliers can establish reproducible links between digital behavior, disease status, and a specific intervention. This distinction will favor companies that specialize by therapeutic context rather than those pursuing broad but weakly differentiated data collection.

Digital Biomarkers Market Regional Analysis

North America North America accounted for approximately 40.6% of global revenue in 2025. The region's position reflects the concentration of digital-health suppliers, pharmaceutical development activity, FDA regulatory pathways, and remote-monitoring reimbursement infrastructure. The U.S. generated USD 1.4 billion in 2024 and USD 1.8 billion in 2025, representing approximately 94.6% of North American revenue. Medicare's expanding remote-monitoring payment base strengthens the operational case for provider adoption, while the FDA framework supports the use of digital health technologies in drug development.

Canada remains an emerging extension of the North American market, with adoption shaped by health-system procurement, clinical research participation, and the ability of suppliers to satisfy Canadian regulatory and data-governance requirements. Its commercial opportunity is likely to be concentrated in interoperable remote-care and research deployments rather than in a separate, stand-alone technology ecosystem.

Europe Europe represented approximately 22.1% of global revenue in 2025, or about USD 1.0 billion. The European market is influenced by the EMA's digital-technology qualification process, national reimbursement systems, and the Medical Device Regulation environment. The EMA's qualification work is significant because it gives pharmaceutical sponsors a route to discuss the acceptability of a digital methodology in medicinal-product development.

Germany provides a structured environment for reimbursed digital-health applications, while the UK combines NHS procurement capacity with national programs in diabetes and connected care. NHS England's hybrid closed-loop implementation strategy is a concrete example of a public health system building connected measurement into care delivery. France, Spain, Italy, and the Netherlands contribute through clinical research capacity, specialist care networks, and participation in broader European regulatory and trial ecosystems. Adoption will vary by country because evidence requirements, procurement practices, and reimbursement conditions remain nationally specific.

Asia Pacific Asia Pacific held approximately 24.6% of 2025 revenue and is forecast to grow at approximately 29.9% CAGR through 2035. Its growth outlook reflects a large chronic-disease population, expanding digital infrastructure, and increasing use of smartphones and wearables. The region is not homogeneous: China's scale, Japan's aging population, India's digital-public-infrastructure programs, Australia's established regulatory environment, and South Korea's technology ecosystem create different routes to adoption.

China is positioned to benefit from large-scale connected-device use and growing interest in software-based medical technologies. Japan's market is shaped by the need to manage age-related cardiovascular and neurological conditions and by regulatory attention to software as a medical device. India's Ayushman Bharat Digital Mission has expanded the country's digital-health infrastructure, reporting hundreds of millions of health accounts and integrated health records ^{[8]Ministry of Health and Family Welfare, Government of India - Ayushman Bharat Digital Mission update, December 2024 - mohfw.gov.in}. Australia provides a regulated environment for digital medical devices and clinical-research participation, while South Korea's adoption is supported by its medical-technology and digital-health capabilities.

Latin America Latin America accounted for approximately 7.1% of the global market in 2025. Brazil and Mexico represent the region's principal scale opportunities, while Argentina has potential through academic and clinical-research participation. Adoption is likely to proceed selectively, with smartphone-based and lower-hardware-intensity approaches offering a more accessible entry point than premium device-and-service models.

The region's commercial challenge is fragmentation. Suppliers must adapt to differences in reimbursement, provider capability, data infrastructure, and affordability. As a result, multinational clinical trials and targeted chronic-care programs may lead broader digital biomarker deployment before region-wide reimbursement pathways emerge.

Middle East and Africa The Middle East and Africa represented approximately 5.6% of the market in 2025. Saudi Arabia and the UAE are likely to be the principal near-term markets because of investment in health-system modernization, connected care, and artificial intelligence-enabled healthcare initiatives. South Africa has an important role as a regional research and clinical-services hub, although deployment conditions differ substantially across the continent.

The opportunity in this region is driven less by a single mature reimbursement model than by uneven investment capacity and the need to build interoperable healthcare infrastructure. Suppliers seeking to enter should distinguish between technology demonstration programs, hospital-network deployments, and scalable reimbursed services; these are commercially different propositions with different evidence and implementation requirements.

The regional mix also changes the product strategy required of suppliers. High-cost, service-intensive platforms may gain initial traction in U.S., European, Japanese, Australian, Saudi, and UAE health-system or trial settings. Mobile-first and lower-hardware approaches may have a broader route in India, Latin America, and other emerging markets, provided that data governance, localization, and clinical-validation requirements are addressed. Geographic expansion will therefore reward modular platforms that preserve methodological consistency while adapting to local workflow and payment realities.

Digital Biomarkers Market Share & Competitive Landscape

The competitive landscape includes specialist digital-biomarker platforms, connected-device companies, clinical-trial technology providers, imaging and neuroinformatics firms, and pharmaceutical companies that use digital measures within development programs. Competition is driven by the credibility of a company's evidence base, its ability to manage multisite data collection, therapeutic-area expertise, regulatory experience, and integration with sponsor or provider workflows.

Ametris combines clinical-grade wearable technology, cloud-based data management, and digital-measure infrastructure for clinical research. Its partnership with uMotif integrated wearable actigraphy with electronic clinical outcome assessments, illustrating the move toward unified patient-data workflows in decentralized and hybrid trials ^{[9]uMotif - uMotif and ActiGraph Partner to Deliver Patient-Centric Solutions with eCOA/ePRO and Wearable Devices for Clinical Trials, February 2023 - umotif.com}.

AliveCor competes in AI-enabled cardiology. Its June 2024 FDA clearances for KAI 12L and the Kardia 12L ECG System reinforce its position in portable, clinically oriented cardiac analysis. Altoida focuses on precision neurology through mobile, sensor-fusion, and augmented-reality assessments; it received FDA Breakthrough Device Designation for an Alzheimer's disease prediction application.

Amgen Inc. is included in the competitive landscape because its therapeutic-development activities create demand for digital endpoints and related evidence-generation capabilities. Its role is better characterized as a pharmaceutical sponsor and potential collaborator than as a pure-play digital-biomarker platform provider.

Adherium Limited focuses on respiratory medication-use monitoring through the Hailie Smartinhaler ecosystem, combining connected sensors, patient applications, and clinical data tools. Aural Analytics developed speech-based measures for cognitive and ALS-related applications, including an FDA-registered computerized cognitive-assessment aid and a Breakthrough Device Designation for Speech Vitals-ALS.

Brainomix applies artificial intelligence to quantitative imaging biomarkers, particularly in stroke and lung disease. Biogen's digital-neurology activities, including its Konectom platform, demonstrate the role of pharmaceutical companies in generating remote neurological performance measures for research and development. Clario provides endpoint technologies across imaging, cardiac safety, eCOA, respiratory, and precision-motion applications, positioning it as an integration partner for complex trial programs.

Empatica competes through medical-grade wearables, including its FDA-cleared EpiMonitor seizure-monitoring system. Evidation Health operates a real-world evidence platform combining direct participant engagement, clinical information, and connected-device signals; its DiSCover study enrolled 10,161 participants to examine digital measures in chronic pain. IXICO focuses on neuroimaging technology and biomarker services for central nervous system trials.

Koneksa provides a sensor-agnostic platform for continuous patient-data collection across clinical trials and supports the transformation of multimodal signals into digital measures. Sonde Health develops vocal-biomarker technology for mental, cognitive, and respiratory health applications, supported by published validation work on mental-fitness vocal measures. Vivo Sense operates as a wearable-sensor contract research organization, supplying digital-measure strategy, device operations, data analysis, and trial-support services.

The competitive advantage of these companies is unlikely to rest on a single device specification. Buyers increasingly require evidence that a platform can deliver data completeness, participant adherence, analytical consistency, and an endpoint that is suitable for a defined clinical or regulatory purpose. This shifts competitive power toward firms that combine technical capability with disease-specific validation and operational execution.

Recent Industry Developments

June 2024 - AliveCor received dual FDA clearances for KAI 12L AI technology and the Kardia 12L ECG System. The cleared system applies AI-supported analysis to a portable reduced-leadset ECG workflow, expanding AliveCor's position in point-of-care cardiac assessment.

March 2024 - Linus Health acquired Aural Analytics. The transaction brought Aural Analytics' speech-based measurement capabilities into Linus Health's cognitive-assessment portfolio, reflecting continued consolidation around multimodal cognitive evaluation.

January 2024 - NHS England published its five-year hybrid closed-loop implementation strategy. The strategy supports phased adoption of connected glucose-management systems for eligible people with type 1 diabetes in England.

March 2023 - The FDA published its framework for the use of digital health technologies in drug and biological product development. The framework addresses digital-health data and endpoints in clinical development under a PDUFA VII commitment.

March 2023 - Aural Analytics received FDA Breakthrough Device Designation for Speech Vitals-ALS. The designation covered a software application intended to support monitoring of ALS progression through speech recordings.